Short answer
AVANOS MEDICAL, INC. (AVNS) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results announcement covering the three months ended March 31, 2026.
AVANOS MEDICAL, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results announcement covering the three months ended March 31, 2026
- Press release furnished as Exhibit 99.1 contains the financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q1 sales $182.2M, up 8.8%, led by Specialty Nutrition Systems sales of $124.0M, up 22.7%
- Specialty Nutrition operating income $23.1M, while Pain Management posted a $1.8M loss versus $0.2M income
- GAAP EPS declined to $0.11 from $0.14; adjusted EPS declined to $0.22 from $0.26
- Operating cash flow swung to a $12.3M outflow; free cash flow declined to a $16.6M outflow
- Pending AIP acquisition at $1.272B enterprise value creates a potential cash-sale catalyst but introduces merger-completion risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AVANOS MEDICAL, INC. 8-K filings
Get the next AVNS 8-K as it lands
Follow AVNS for push alerts, or ask the research agent what this filing means.